Medicine composition for preventing and treating diabetes mellitus and its use

Abstract

The present invention relates to a drug compound for preventing and treating type I diabetes and its application. The drug compound includes 1) a polypeptide capable of treating type I diabetes; A nucleic acid vaccine of a polypeptide having at least 50% homology to the B7-1wa polypeptide of the negative regulatory protein CTLA-4. The drug complex according to the present invention can effectively prevent and treat diabetes. The drug complex of the present invention can promote the regeneration of B cells and at the same time control the autoimmune process, so that patients at high risk of developing type 1 diabetes can be completely exempted from the disease, or completely cured in patients who are newly diagnosed with type 1 diabetes or those who have had it for many years type 1 diabetics.

Description

technical field [0001] The invention relates to a drug compound for preventing and treating type I diabetes and its application. Specifically, the present invention relates to a polypeptide comprising 1) a polypeptide capable of treating type I diabetes; 2) comprising at least 50% homology to proinsulin, GAD65, and a B7-1wa polypeptide that can bind to T cell negative regulatory protein CTLA-4 A drug compound of a nucleic acid vaccine of a specific polypeptide for the prevention and treatment of type I diabetes, and its application. Background technique [0002] Diabetes is one of the main causes of human death and seriously endangers human health. Type I diabetes and type II diabetes are the two main forms of diabetes. Apoptosis, or programmed death, is the main cause of islet cell death in type I and type II diabetes. Both type I and type II diabetics exhibit progressive islet B-cell mass loss and decreased B-cell function. [0003] Glucagon-like peptide (GLP-1, amino ...

AI Technical Summary

Problems solved by technology

There may be many negative effects in terms of clinical application, such as the introduction of genes into transplanted islets will be limited by the anti-islet immune response and the relatively short expression time of some plasmids

In addition, insulin or insulin analogues have been delivered to the liver, muscle, and other tissues by gene therapy, but the desired physiological regulation of blood glucose levels has not been achieved

Alternative therapies involve the in vivo delivery of genes such as PDX-1 to induce hepatocytes to differentiate into islet cells, but initial successful experiments have been difficult to replicate

In recent years, many gene-based therapies have indeed been proposed, but almost all of these therapies are based on viral vector gene transfer, have many limitations such as pathogenicity and immunogenicity, and none of them can be applied to humans

Images